文献速递神经免疫

多发性硬化治疗新视野:2025及未来

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
PubMed 文献 · Ann Neurol · 2025-06-06

本文总结多发性硬化(MS)领域的近期进展,指出基于免疫学、神经生物学、遗传学及疾病触发因素的理解,疗法选择性和安全性不断提高,治疗焦点已从传统治疗扩展至预防与修复的现实可能。MS已从西方最常见的青年致残疾病转变为多数新诊断患者可预期无残疾生活。

要点

  • MS治疗选择性和安全性持续提升,已从传统治疗扩展至预防与修复。
  • 基础免疫学、神经生物学和遗传学进展推动了疗法发展。
  • 多数新诊断MS患者可预期无残疾生活。

核心结论

  • MS治疗领域取得重大进展,使多数新诊断患者可预期无残疾生活。

研究设计与样本

  • 综述文章,总结MS治疗相关近期进展,未报告系统检索范围。

主要发现

  • 疗法选择性和安全性不断提高,治疗焦点扩展至预防和修复。

临床怎么用

  • 临床可关注选择性和安全性更高的疗法,并考虑预防与修复策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on treatment, adding realistic possibilities for prevention and repair. Here, we summarize recent advances that have together transformed the disease from the most common crippler of young adults in the western world to its place today as a condition in which most newly diagnosed patients can anticipate lives free from disability. ANN NEUROL 2025;98:317-328.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Sabatino JJ, Cree BAC, Hauser SL, et al. New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond. Ann Neurol. 2025. PMID: 40474602. doi:10.1002/ana.27270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。